+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Eylea Market by Therapeutic Class, Mode Of Administration, Patient Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015393
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Eylea Market grew from USD 6.89 billion in 2023 to USD 7.25 billion in 2024. It is expected to continue growing at a CAGR of 6.83%, reaching USD 10.95 billion by 2030.

Eylea, known for its role in treating ocular diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME), represents a crucial segment in the pharmaceutical and ophthalmologic market. The therapy works by inhibiting vascular endothelial growth factor (VEGF), effectively slowing down the progression of these debilitating eye conditions. Given the increasing prevalence of diabetes and associated eye disorders, the necessity for Eylea is rising. It is mainly applied in ophthalmology clinics and hospitals where monitoring and long-term treatment are essential, providing physicians with a robust means to manage disease progression. The end-use scope includes individual patients, healthcare institutions, and specialized eye care centers. Market insights show a robust growth trajectory influenced by rising geriatric populations, increased healthcare spending, and advanced diagnostic technologies improving early detection. However, growth potential is mitigated by challenges such as high treatment costs, stringent regulatory approvals, and competitive threats from emerging biosimilars and alternative therapies. To tackle these constraints, companies can invest in research focusing on enhanced drug delivery systems, like sustained-release formulations, to improve patient compliance and outcomes. Collaborative innovation and partnerships with tech companies can yield breakthroughs in personalized medicine, combining genetic insights with targeted therapies. Healthcare platforms designed for better patient engagement and AI-driven analytics to monitor effectiveness can offer significant competitive advantages. The market demands innovation in affordability and accessibility, creating an opportunity for biosimilars while also focusing on broader geographical expansions to tap into underserved markets. The regulatory landscape remains a challenge, urging firms to prioritize transparent and rigorous data collections in clinical trials to expedite approvals. Overall, while growth prospects are promising, they will require agile strategies that quickly adapt to evolving market needs.

Understanding Market Dynamics in the Eylea Market

The Eylea Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
    • Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
    • Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
    • Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
  • Market Restraints
    • Limited patient accessibility and affordability of advanced anti-VEGF therapies
    • Increasing competition from emerging biosimilars reducing market share of established brands
  • Market Opportunities
    • Developing patient education programs to enhance understanding of retinal disease management
    • Leveraging big data analytics for early detection and monitoring of retinal conditions
    • Promoting home-based care solutions to increase patient convenience and adherence
  • Market Challenges
    • Competition from alternative treatment options for retinal diseases impacting Eylea's market share
    • Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions

Exploring Porter’s Five Forces for the Eylea Market

Porter’s Five Forces framework further strengthens the insights of the Eylea Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Eylea Market

External macro-environmental factors deeply influence the performance of the Eylea Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Eylea Market

The Eylea Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Eylea Market

The Eylea Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Eylea Market

The Eylea Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Eylea Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Alexion Pharmaceuticals, Inc., Allergan, Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Eylea Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapeutic Class
    • Age-Related Macular Degeneration
    • Diabetic Macular Edema
    • Retinal Disorders
  • Mode Of Administration
    • Intravitreal Injection
    • Ocular Implants
      • Biodegradable
      • Non-Biodegradable
  • Patient Type
    • Adult
    • Geriatric
    • Pediatric
  • End-User
    • Ambulatory Surgical Centers
    • Hospitals
    • Ophthalmic Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
5.1.1.2. Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
5.1.1.3. Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
5.1.1.4. Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
5.1.2. Restraints
5.1.2.1. Limited patient accessibility and affordability of advanced anti-VEGF therapies
5.1.2.2. Increasing competition from emerging biosimilars reducing market share of established brands
5.1.3. Opportunities
5.1.3.1. Developing patient education programs to enhance understanding of retinal disease management
5.1.3.2. Leveraging big data analytics for early detection and monitoring of retinal conditions
5.1.3.3. Promoting home-based care solutions to increase patient convenience and adherence
5.1.4. Challenges
5.1.4.1. Competition from alternative treatment options for retinal diseases impacting Eylea's market share
5.1.4.2. Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Eylea Market, by Therapeutic Class
6.1. Introduction
6.2. Age-Related Macular Degeneration
6.3. Diabetic Macular Edema
6.4. Retinal Disorders
7. Eylea Market, by Mode Of Administration
7.1. Introduction
7.2. Intravitreal Injection
7.3. Ocular Implants
7.3.1. Biodegradable
7.3.2. Non-Biodegradable
8. Eylea Market, by Patient Type
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Eylea Market, by End-User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.4. Ophthalmic Clinics
10. Americas Eylea Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Eylea Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Eylea Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. EYLEA MARKET RESEARCH PROCESS
FIGURE 2. EYLEA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL EYLEA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL EYLEA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EYLEA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. EYLEA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. EYLEA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL EYLEA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL EYLEA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. EYLEA MARKET DYNAMICS
TABLE 7. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL EYLEA MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL EYLEA MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL EYLEA MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL EYLEA MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL EYLEA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL EYLEA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL EYLEA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. CANADA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 42. CANADA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. CANADA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 44. CANADA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. MEXICO EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 47. MEXICO EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. MEXICO EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 49. MEXICO EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. CHINA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 69. CHINA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CHINA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 71. CHINA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CHINA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. INDIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 74. INDIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. INDIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 76. INDIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. JAPAN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 84. JAPAN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. JAPAN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 86. JAPAN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. THAILAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 114. THAILAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. THAILAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 116. THAILAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. THAILAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. DENMARK EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. DENMARK EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. DENMARK EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 132. DENMARK EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. EGYPT EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 135. EGYPT EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. EGYPT EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 137. EGYPT EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. FINLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. FINLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. FINLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 142. FINLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. GERMANY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. GERMANY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. ITALY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 160. ITALY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. ITALY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 162. ITALY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. NORWAY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 175. NORWAY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. NORWAY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 177. NORWAY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. NORWAY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. POLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. POLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. POLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 182. POLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. POLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 185. QATAR EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. QATAR EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 187. QATAR EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. TURKEY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 220. TURKEY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. TURKEY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 222. TURKEY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. EYLEA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 235. EYLEA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Eylea Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Alcon Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information